

# Gregory Cote

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7267706/publications.pdf>

Version: 2024-02-01

14  
papers

460  
citations

840776

11  
h-index

1058476

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

721  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4491-4499.	7.0	112
2	Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma. <i>Oncotarget</i> , 2015, 6, 11139-11149.	1.8	89
3	miR-15b modulates multidrug resistance in human osteosarcoma <i>in vitro</i> and <i>in vivo</i> . <i>Molecular Oncology</i> , 2017, 11, 151-166.	4.6	47
4	The Width of the Surgical Margin Does Not Influence Outcomes in Extremity and Truncal Soft Tissue Sarcoma Treated With Radiotherapy. <i>Oncologist</i> , 2016, 21, 1269-1276.	3.7	41
5	Preoperative radiation therapy combined with radical surgical resection is associated with a lower rate of local recurrence when treating unifocal, primary retroperitoneal liposarcoma. <i>Journal of Surgical Oncology</i> , 2016, 114, 814-820.	1.7	27
6	NVP-AE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function. <i>British Journal of Pharmacology</i> , 2016, 173, 613-626.	5.4	26
7	Prognostic Factors in Dedifferentiated Chondrosarcoma: A Retrospective Analysis of a Large Series Treated at a Single Institution. <i>Sarcoma</i> , 2019, 2019, 1-10.	1.3	23
8	Chordoma: Current status, problems, and future directions. <i>Current Problems in Cancer</i> , 2021, 45, 100771.	2.0	20
9	Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma. <i>PLoS ONE</i> , 2014, 9, e93996.	2.5	19
10	The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies. <i>Life Science Alliance</i> , 2021, 4, e202000808.	2.8	18
11	ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION. <i>Neuro-Oncology</i> , 2018, 20, vi18-vi18.	1.2	12
12	Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT. <i>Clinical Cancer Research</i> , 2022, 28, 298-307.	7.0	12
13	Clinical outcomes for patients after surgery and radiation therapy for mesenchymal chondrosarcomas. <i>Journal of Surgical Oncology</i> , 2016, 114, 982-986.	1.7	11
14	Primary Spindle Cell Sarcoma of the Lung with MGA::NUTM1 Fusion: An Extremely Rare Case of a Potentially Emerging Entity and Review of the Literature. <i>International Journal of Surgical Pathology</i> , 2022, 30, 931-938.	0.8	3